# Triveni Bio

> Triveni Bio is a clinical-stage biotechnology company in Watertown, Massachusetts building first-in-class antibody therapeutics for immunological and inflammatory (I&I) diseases. Born from the 2023 merger of Amagma Therapeutics and Modify Therapeutics, the company pairs a genetics-informed approach with advanced antibody engineering to target root-cause biology rather than just downstream inflammation. Its lead program, TRIV-509, is a half-life-extended monoclonal antibody that inhibits active kallikreins 5 and 7 (KLK5/7) and is in a global Phase 2 proof-of-concept study for moderate-to-severe atopic dermatitis. Backed by roughly $223M across Series A and Series B rounds, Triveni aims to repair the skin barrier and break what it calls efficacy ceilings in dermatology and beyond.

- **Founded:** 2023
- **Headquarters:** Watertown, Massachusetts, United States
- **Founders:** Tillman Gerngross (Co-founder (via Amagma Therapeutics)), Leonard Zon (Co-founder (via Amagma Therapeutics))
- **Team size:** ~54 employees
- **Products:** TRIV-509, TRIV-573, Genetics-informed antibody platform
- **Notable:** Raised approximately $223M total across Series A ($92M) and Series B ($115M) within roughly a year., Advanced TRIV-509 from formation to a global Phase 2 proof-of-concept study in atopic dermatitis in under two years., Dosed first healthy volunteers in the TRIV-509 first-in-human trial and later dosed the first Phase 2 subject.

## Products & services

- **TRIV-509** — Lead candidate: a first-in-class, dual-specific, half-life-extended monoclonal antibody that inhibits active kallikreins 5 and 7 (KLK5/7). In a global Phase 2 proof-of-concept study for moderate-to-severe atopic dermatitis, designed to repair the skin barrier. Showed superior efficacy versus IL-4R inhibition in preclinical models.
- **TRIV-573** — Next-generation bispecific antibody combining KLK5/7 inhibition with IL-13 blockade, intended to pair barrier repair with potent anti-inflammatory action. Expected to enter the clinic around Q2 2026.
- **Genetics-informed antibody platform** — Discovery engine built on three pillars - a genetics-informed approach, advanced antibody engineering, and pioneering novel biology - used to identify and validate therapeutic targets for I&I disorders.

## Achievements

- Raised approximately $223M total across Series A ($92M) and Series B ($115M) within roughly a year.
- Advanced TRIV-509 from formation to a global Phase 2 proof-of-concept study in atopic dermatitis in under two years.
- Dosed first healthy volunteers in the TRIV-509 first-in-human trial and later dosed the first Phase 2 subject.
- Presented translational data at the 2025 EADV Congress demonstrating novel KLK5/7 biology in patient samples.
- Demonstrated superior efficacy versus IL-4R inhibition in multiple preclinical atopic dermatitis models.

## Latest updates

- **2025-10** — Dosed first subject in global Phase 2 proof-of-concept study of TRIV-509 in atopic dermatitis and presented translational data at the 2025 EADV Congress.
- **2025** — Dosed first healthy volunteers in the TRIV-509 first-in-human trial alongside preclinical data presentations validating KLK5/7 biology.
- **2024-10** — Raised $115M Series B led by Goldman Sachs Alternatives to expand the I&I pipeline.
- **2023-11** — Launched publicly with $92M Series A, formed via merger of Amagma Therapeutics and Modify Therapeutics.

## Links

- Website: https://triveni.bio
- LinkedIn: https://www.linkedin.com/company/triveni-bio

---

Profile page: https://yespress.io/triveni-bio
Published by YesPress — https://yespress.io
Last updated: 2026-06-10